Anavex Encouraged by Scientific Data Confirming Sigma-1 Receptor’s Beneficial Direct Interaction with Cannabinoid Receptor
Anavex Begins Enrollment of Alzheimer’s Patients in Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS
Anavex Announces Positive Phase 1 Data for ANAVEX 2-73, Lead Candidate for the Treatment of Alzheimer’s
Anavex Receives Regulatory Approval to Initiate Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS for Alzheimer’s disease